Medroxyprogesterone Acetate
"Medroxyprogesterone Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.
| Descriptor ID |
D017258
|
| MeSH Number(s) |
D04.210.500.745.745.654.829.395.700.500
|
| Concept/Terms |
Medroxyprogesterone Acetate- Medroxyprogesterone Acetate
- Depo-Medroxyprogesterone Acetate
- Depo Medroxyprogesterone Acetate
- 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate
- 6 alpha Methyl 17alpha hydroxyprogesterone Acetate
- (6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione
- Medroxyprogesterone 17-Acetate
- Medroxyprogesterone 17 Acetate
|
Below are MeSH descriptors whose meaning is more general than "Medroxyprogesterone Acetate".
Below are MeSH descriptors whose meaning is more specific than "Medroxyprogesterone Acetate".
This graph shows the total number of publications written about "Medroxyprogesterone Acetate" by people in this website by year, and whether "Medroxyprogesterone Acetate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Medroxyprogesterone Acetate" by people in Profiles.
-
The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the Women's Health Initiative clinical trials. Menopause. 2023 01 01; 30(1):28-36.
-
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 05 15; 27(10):2734-2741.
-
Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. J Natl Cancer Inst. 2017 09 01; 109(9).
-
Luteolin suppresses development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. Oncol Rep. 2016 Feb; 35(2):825-32.
-
Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol. 2014 Nov; 33(6):543-53.
-
Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause. 2013 Mar; 20(3):254-60.
-
Intra-amniotic LPS and antenatal betamethasone: inflammation and maturation in preterm lamb lungs. Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15; 302(4):L380-9.
-
Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: a pilot study. J Pediatr Adolesc Gynecol. 2010 Aug; 23(4):209-14.
-
Herpes simplex virus type 2-induced mortality following genital infection is blocked by anti-tumor necrosis factor alpha antibody in CXCL10-deficient mice. J Virol. 2008 Oct; 82(20):10295-301.
-
A confusing case of confusion. Acute porphyrias. J Okla State Med Assoc. 2008 Apr; 101(4):85-6, 89-90.